Skip to main
UPB

UPB Stock Forecast & Price Target

UPB Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Upstream Bio is expected to see strong demand for verekitug upon its potential approval, as the drug has shown promising results in Phase 2 trials for multiple inflammatory diseases. With a strong cash position and plans for strategic development, the company is well-equipped to bring this potentially game-changing treatment to market, which could lead to significant revenue growth and a boost in stock valuation. The positive outlook on Upstream Bio's stock is based on the company's innovative approach to addressing unmet needs in the respiratory disease space, and the potential for verekitug to become a market-leading biologic drug.

Bears say

Upstream Bio is facing elevated financing and commercial risks due to investor sentiment, along with a 13% discount rate, resulting in a reduced price target of $25. The company also faces competition and regulatory risks, as well as potential challenges with maintaining intellectual property protection and setting prices for its products. However, the company's lead candidate verekitug has shown promising results in clinical trials for various inflammatory diseases, and its unique TSLP targeting mechanism may offer a competitive advantage.

UPB has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Upstream Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Upstream Bio Inc (UPB) Forecast

Analysts have given UPB a Buy based on their latest research and market trends.

According to 6 analysts, UPB has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Upstream Bio Inc (UPB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.